VK2735

VK2735 is a dual agonist of the GLP-1 receptor and GIP receptor, with a similar mechanism of action as tirzepatide, which acts on the same receptors. It is injectable and is being developed by Viking Therapeutics.^[1][2][3]

References

1. Mariam E Sunny, Bhanvi Satija (2024-02-27). "Viking Therapeutics notches success with weight-loss drug trial, shares double". Reuters. Retrieved 2024-03-09.
2. Goldenberg, Ronald M.; Teoh, Hwee; Verma, Subodh (2023-08-21). "Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data". Current Opinion in Cardiology. 38 (6). Ovid Technologies (Wolters Kluwer Health): 539–545. doi:10.1097/hco.0000000000001084. ISSN 0268-4705. PMID 37792556.
3. Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists". Obesity Reviews. 25 (3): e13663. doi:10.1111/obr.13663. ISSN 1467-7881. PMID 37968541.